Medical Devices Neutral 5

Nortech Medical Sales Jump 36% as CapsoVision Tracks 176K Patients

Nortech Systems posted 36% medical device growth, and CapsoVision renewed four major hospital systems while surpassing 176,000 patients imaged. The reports point to resilient demand for medical devices and imaging despite industrial and defense weakness.

· 5 min read ·

Beat this week

Last 7 days Ā· Medical Devices

8 stories
5.1 avg impact
13% positive
0% negative
vs prior 7 days -2 -2 stories vs prior 7 days

Impact 5.1/10, unchanged. Counts are stories in our record, not a market forecast.

Open the change report

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 13 percentage points.

  • 13% positive
  • 88% neutral

This story sits in Medical Devices — the counts compare this beat's last 7 days with the previous 7 in our verified record, not a market forecast.

Figures are computed live from our source-verified story record (as of ) The volume change compares this window with the prior 7 days in the same record. — see our methodology for how impact and sentiment are derived.

Healthcare briefing

Key takeaways

5 impact
Neutralsentiment
5min read
  1. Nortech Systems posted 36% medical device growth, and CapsoVision renewed four major hospital systems while surpassing 176,000 patients imaged.
  2. The reports point to resilient demand for medical devices and imaging despite industrial and defense weakness.

In this briefing

Mentioned

Key Intelligence

Key Facts

  1. 1Nortech Systems Q2 2026 net sales rose 9.3% to $33.5M; gross profit increased to $5.7M from $4.8M, expanding gross margin 120 bps to 17.0%.
  2. 2Nortech's Medical Device segment sales grew 36% YoY; Medical Imaging rose 12.2%, while Industrial fell 4.7% and Aerospace/Defense declined 12.8% in Q2 but is up 8.7% year to date.
  3. 3Higher incentive and stock-based compensation expenses limited Nortech operating income to $623,000; management cited backlog growth and restructuring benefits as supporting factors.
  4. 4CapsoVision Q2 2026 revenue was $3.6M, up 10% from $3.3M; CapsoCam Plus capsule sales rose 13% YoY with 8,845 capsules shipped vs 7,856 in the prior-year period.
  5. 5CapsoVision cumulative patients imaged surpassed 176,000 as of June 30, 2026, up 23% from more than 143,000 at the end of Q2 2025.
  6. 6Andersen Group Q2 revenue reached $217.7M, up 23.7% and above guidance; organic growth was 20.6%, and business tax services grew 36.9% and represented 39.2% of total revenue.
Patients Imaged with CapsoCam Plus
176,000 +23% YoY

Cumulative as of June 30, 2026

CapsoVision

Company

Analysis

For health systems and gastroenterology networks, CapsoVision's renewals with M Health Fairview, Henry Ford, University of Colorado Anschutz, and Providence Swedish signal that capsule endoscopy is becoming a standard option for small bowel imaging. Nortech's 36% medical device growth and its key customer stocking program indicate manufacturers are investing in supply assurance and shorter lead times. These Q2 results suggest healthcare capital and diagnostic demand remain a bright spot amid broader industrial softness.

The Q2 2026 earnings season delivered three distinct reports across medical device manufacturing, capsule endoscopy, and professional services. Nortech Systems (NASDAQ:NSYS) reported net sales of $33.5 million, up 9.3% year over year from $30.7 million, with gross profit increasing to $5.7 million from $4.8 million and gross margin expanding 120 basis points to 17.0%. The company's medical device segment was the standout, growing 36% year over year, while medical imaging rose 12.2%. Industrial sales declined 4.7% due to customer inventory adjustments and manufacturing transfers to Monterrey, Mexico, and aerospace/defense fell 12.8% in the quarter, though that segment remains up 8.7% year to date. CapsoVision (NASDAQ:CV) reported Q2 revenue of $3.6 million, up approximately 10% from $3.3 million a year earlier, driven by a 13% increase in CapsoCam Plus capsule sales partially offset by a roughly 3% decline in average selling prices. The company shipped 8,845 capsules versus 7,856 in the prior-year period, and surpassed 176,000 cumulative patients imaged as of June 30, 2026, a 23% increase from more than 143,000 a year earlier. Andersen Group (NYSE:ANDG) reported revenue of $217.7 million, up 23.7% year over year and above its prior guidance of $190 million to $205 million, with organic growth of 20.6% and first-half revenue of approximately $458 million, up 19.4%.

Andersen Group (NYSE:ANDG) reported revenue of $217.7 million, up 23.7% year over year and above its prior guidance of $190 million to $205 million, with organic growth of 20.6% and first-half revenue of approximately $458 million, up 19.4%.

The common thread across these reports is bifurcation: healthcare-related demand remains resilient while certain industrial and defense markets face inventory destocking. Nortech's medical device growth of 36% and medical imaging growth of 12.2% reflect higher demand from existing customers and continued ramp-ups of new programs. Management specifically cited a stocking program with a key customer designed to improve product availability and shorten lead times. By contrast, industrial sales fell 4.7% as customers worked through inventory and Nortech transferred manufacturing activity to Monterrey, and aerospace/defense declined 12.8% because one customer reduced post-COVID inventory levels. Yet backlog growth and restructuring benefits from late 2024 and early 2025 supported results. Higher incentive and stock-based compensation expenses, however, limited operating income to just $623,000, underscoring that gross margin improvement at 17.0% remains thin for a contract manufacturer.

CapsoVision's results highlight sustained adoption of capsule endoscopy in gastroenterology. The company renewed relationships with M Health Fairview University of Minnesota Medical Center, Henry Ford Hospital, the University of Colorado Anschutz Medical Campus, and Providence Swedish. Notably, Providence Swedish made CapsoCam the most-used capsule in Washington state hospitals. The 13% increase in capsule sales and 12.6% increase in units shipped (8,845 versus 7,856) came despite a 3% decline in average selling prices, suggesting volume growth and competitive pricing dynamics. International expansion includes a dedicated commercial organization in Germany, and management is advancing artificial intelligence software rollout and development programs for colon and upper gastrointestinal applications, which could materially expand the addressable market beyond small bowel imaging.

What to Watch

Andersen Group's Q2 performance demonstrates pricing power and productivity in professional services. Revenue of $217.7 million exceeded guidance, and the company's approximately 20.5% organic growth rate was the strongest second-quarter percentage growth in its 24-year history. Business tax services led with 36.9% revenue growth and accounted for 39.2% of total revenue, while private client services grew approximately 17%. Chargeable hours increased 5% in the first half, revenue per professional rose 16.4%, and rate per hour increased 10.1%. Andersen implemented a rate adjustment in July and introduced a 3% tax surcharge for certain client contracts signed beginning in the second quarter. However, the company reported a GAAP net loss of $10.1 million for the quarter, likely reflecting acquisition-related costs or compensation expenses, and management noted that net client growth was more modest than gross additions of over 1,300 clients because certain assignments were completed and less productive relationships were ended.

Taken together, the three reports suggest a market environment in which healthcare and services businesses are posting solid growth and absorbing pricing increases, while goods-related industrial customers are still managing inventory levels. Nortech's dependence on medical device demand is now clearer than ever; if that segment slows, industrial and aerospace/defense have not yet fully recovered. CapsoVision's patient milestone and AI pipeline provide a long-term growth narrative, but revenue remains small at $3.6 million, so scale and reimbursement dynamics will be critical. Andersen's organic growth and rate increases are notable, but the GAAP net loss and selective client retention bear watching. Forward-looking indicators include Nortech's backlog conversion and tariff/trade policy exposure around Monterrey, CapsoVision's AI software regulatory progress for colon and upper GI applications, and Andersen's ability to sustain pricing power into the second half after July rate adjustments.

Cite This Page

"Nortech Medical Sales Jump 36% as CapsoVision Tracks 176K Patients." Healthcare Intelligence Brief, August 14, 2026. https://gethealthbrief.com/story/nortech-capsovision-q2-2026-healthcare-device-growth

How we covered this story

Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≄2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.

Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.

Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.

See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.